The PROGRESS study: rationale and design

Medicine and Dentistry

• Patient 100%
• Apoplexy 100%
• Therapeutic Procedure 66%
• ACE Inhibitor 50%
• Transient Ischemic Attack 50%
• Cardiovascular System 33%
• Disability 33%
• Inpatient 33%
• Brain Ischemia 33%
• Intervention Study 33%
• Contraindication 33%
• Perindopril 33%
• Blood Pressure Reduction 33%
• Amaurosis 16%
• Dementia 16%
• Blood Pressure 16%
• Cognition 16%
• Death 16%
• Follow up 16%
• Dependent Personality Disorder 16%
• Systolic Blood Pressure 16%
• Indapamide 16%
• Diastolic Blood Pressure 16%
• Diuretic Agent 16%
• Treatment Duration 16%
• Cerebrovascular Disease 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Dipeptidyl Carboxypeptidase Inhibitor 50%
• Transient Ischemic Attack 50%
• Disability 33%
• Perindopril 33%
• Brain Ischemia 33%
• Controlled Clinical Trial 33%
• Blindness 16%
• Dementia 16%
• Dependent Personality Disorder 16%
• Death 16%
• Indapamide 16%
• Diuretic Agent 16%
• Cerebrovascular Disease 16%